Adverse events in patients with liver cancer.

abstract：:We investigated whether Ukrain modulates the malignant phenotype of clear cell renal cell carcinoma (ccRCC) cells Caki-1, Caki-2, and ACHN treated with four doses (5, 10, 20, and 40 μmol/l) for 24 and 48 h. The epithelial-to-mesenchymal transition markers E-cadherin, β-catenin, and vimentin were analyzed by immunofluo...

journal_title：Anti-cancer drugs

authors： Gagliano N,Pettinari L,Aureli M,Martinelli C,Colombo E,Costa F,Carminati R,Volpari T,Colombo G,Milzani A,Dalle-Donne I,Gioia M

更新日期：2011-09-01 00:00:00

abstract：:Anti-tubulin couplets have activity in hormone-resistant prostate cancer. This study was designed to define the dose-limiting toxicity (DLT) and recommended phase II dose (RPTD) of the unique triplet combination of paclitaxel, estramustine phosphate (EMP) and vinorelbine (Pacl-E-Vin). Patients with advanced malignanci...

journal_title：Anti-cancer drugs

authors： Sewak S,Chachoua A,Hamilton A,Taneja S,Lee J,Utate M,Sorich J,Muggia FM

更新日期：2003-01-01 00:00:00

abstract：:Since the early 1990s, mitoxantrone has been used as a chemotherapeutic agent for adjuvant intravesical treatment following transurethral resection of superficial transitional cell carcinomas of the bladder. Although its efficacy as adjuvant intravesical therapy remains questionable and its use has not gained wide acc...

journal_title：Anti-cancer drugs

authors： Giannakopoulos S,Pantazis T,Kalaitzis C,Antoniou D,Patris E,Touloupidis S

更新日期：2008-03-01 00:00:00

abstract：:Taxanes have had a profound impact on the management of genitourinary tumors. In the perioperative and metastatic setting in bladder cancer, taxanes such as paclitaxel have an established role in combination chemotherapy strategies to improve survival. In metastatic prostate cancer, docetaxel was the only treatment, u...

journal_title：Anti-cancer drugs

authors： Balar AV

更新日期：2014-05-01 00:00:00

abstract：:We have previously reported the cytotoxic effects of chalcone A1, derived from 1-naphthaldehyde, in leukemia cell lines. On the basis of these findings, the main aim of this study was to elucidate some of the molecular mechanisms involved in apoptosis induced by chalcone A1 toward K562 and Jurkat cells. In both cell l...

journal_title：Anti-cancer drugs

authors： Maioral MF,Moraes AC,Sgambatti KR,Mascarello A,Chiaradia-Delatorre LD,Yunes RA,Nunes RJ,Santos da Silva MC

更新日期：2016-09-01 00:00:00

abstract：:Metformin, an oral antidiabetic agent, has been reported to potentiate chemotherapeutic-induced cytotoxicity. In this study, we investigated the effects and molecular mechanisms of metformin in sensitizing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human bladder cancer cells. ...

journal_title：Anti-cancer drugs

authors： Zhang T,Wang X,He D,Jin X,Guo P

更新日期：2014-09-01 00:00:00

abstract：:Cancer invasion and metastasis are highly complex processes and a serine protease urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system has been postulated to play a central role in the mediation of cancer progression. Of note, malignant tumor urokinase-type plasminogen activator an...

journal_title：Anti-cancer drugs

authors： Nozaki S,Endo Y,Nakahara H,Yoshizawa K,Ohara T,Yamamoto E

更新日期：2006-11-01 00:00:00

abstract：:A drug-resistant cell line (EAC/Dox) was developed by repeated exposure of Ehrlich ascites carcinoma cells to Doxorubicin (Dox) in vivo in male albino Swiss mice (6-8 weeks old). The weekly i.p. injections of Dox to mice (2 or 4 mg/kg/week for 4 months) gave rise to Dox-resistant cell line EAC/Dox, which displayed typ...

journal_title：Anti-cancer drugs

authors： Choudhuri SK,Chatterjee A

更新日期：1998-10-01 00:00:00

abstract：:Hemolytic uremic syndrome (HUS) is a rare clinical and biological entity. HUS has been reported after several anticancer chemotherapies and most often after mitomycin C-based chemotherapy regimens. Little information is available concerning the occurrence and outcome of this syndrome after administration of more recen...

journal_title：Anti-cancer drugs

authors： Gross M,Hiesse C,Kriaa F,Goldwasser F

更新日期：1999-07-01 00:00:00

abstract：:Our previous studies have shown that arsenic trioxide (As2O3), a novel anti-cancer agent, may be active against urothelial carcinomas. A series of bladder urothelial carcinoma cells with progressive As2O3 resistance were established and studied to reveal molecular events in relation to the mechanisms of resistance to ...

journal_title：Anti-cancer drugs

authors： Hour TC,Huang CY,Lin CC,Chen J,Guan JY,Lee JM,Pu YS

更新日期：2004-09-01 00:00:00

abstract：:Non-resectable biliary tract cancer is associated with poor prognosis due to widespread resistance to chemotherapeutic agents and radiotherapy. It is therefore essential to explore new therapeutic approaches like the inhibition of tyrosine kinases. The aim of this study was to determine the expression of c-kit and pla...

journal_title：Anti-cancer drugs

authors： Wiedmann M,Kreth F,Feisthammel J,Deininger M,Mössner J,Caca K

更新日期：2003-10-01 00:00:00

abstract：:Neurofibromatosis type 2 (NF2) is an autosomal dominant condition caused by pathogenic variants in the NF2 gene. To date, cytotoxic chemotherapy has no established role in the treatment of NF-2. Historical case reports of malignant schwannomas have documented responses to chemotherapies with cyclophosphamide, vincrist...

journal_title：Anti-cancer drugs

authors： Nigro O,Coppola A,Tartaro T,Tuzi A,Vallini I,Pinotti G

更新日期：2020-08-01 00:00:00

abstract：:Para-toluenesulfonamide (PTS), active ingredient being PTS, is a new anticancer drug applied through local intratumoral injection. The aim of this phase II clinical trial was to investigate the response and toxicity of standard gemcitabine (GEM) plus cisplatin (CIS) chemotherapy with concurrent intratumoral injection ...

journal_title：Anti-cancer drugs

authors： He J,Ying W,Yang H,Xu X,Shao W,Guan Y,Jiang M,Wu Y,Zhong B,Wang D,Tucker S,Zhong N

更新日期：2009-10-01 00:00:00

abstract：:The antiproliferative effect of simvastatin on tumor cells has been speculated to be by intracellular signal inhibition through 3-hydroxy-3-methylglutaryl acetyl coenzyme A reductase. We examined the killing effect of simvastatin on imatinib-sensitive and resistant chronic myelogenous leukemia (CML) cells (three kinds...

journal_title：Anti-cancer drugs

authors： Oh B,Kim TY,Min HJ,Kim M,Kang MS,Huh JY,Kim Y,Lee DS

更新日期：2013-01-01 00:00:00

abstract：:The aim of this study was to establish xenograft models of tumor in mice bladder and evaluate the antitumor efficacy of ampelopsin sodium (Amp-Na). A total of 2×10 human bladder carcinoma EJ cells and murine sarcoma 180 cells were instilled into the bladder of BALB/c nu/nu mice and Swiss mice after preconditioning to ...

journal_title：Anti-cancer drugs

authors： Zhang B,Dong S,Cen X,Wang X,Liu X,Zhang H,Zhao X,Wu Y

更新日期：2012-07-01 00:00:00

abstract：:It is crucial to incorporate new and more potent antineoplastic agents in treating non-Hodgkin's lymphoma since standard chemotherapy fails to cause a significant increase in the survival rate. A potential chemotherapeutic agent is dolastatin 10; hence, the objective of our study is to investigate the effect of the an...

journal_title：Anti-cancer drugs

authors： Maki A,Mohammad R,Raza S,Saleh M,Govindaraju KD,Pettit GR,al-Katib A

更新日期：1996-05-01 00:00:00

abstract：:Multi-targeted antifolate (MTA) is an anti-metabolite with useful activity in the treatment of non-operable patients presenting with non-small cell lung cancer. Its good efficacy and tolerability profile as first-line therapy was demonstrated in phase II studies of MTA as monotherapy. The use of MTA as second-line the...

journal_title：Anti-cancer drugs

authors： Le Chevallier T

更新日期：2001-07-01 00:00:00

abstract：:Neuroblastoma is one of the most common cancers in infancy, arising from the neuroblasts during embryonic development. This cancer is difficult to treat and resistance to chemotherapy is often found; therefore, clinical trials of novel therapeutic approaches, such as targeted-cancer signaling, could be an alternative ...

journal_title：Anti-cancer drugs

authors： Suebsoonthron J,Jaroonwitchawan T,Yamabhai M,Noisa P

更新日期：2017-06-01 00:00:00

abstract：:The aim of this study was to evaluate the efficacy and tolerability of the combination of paclitaxel and nedaplatin in patients with advanced esophageal cancer. Patients (n = 310) with recurrent or metastatic esophageal squamous cell carcinoma, who had a maximum of one previous chemotherapy regimen, were enrolled in t...

journal_title：Anti-cancer drugs

authors： Du J,Hu C,Zhang Y,Hu B,Wang F,Zhang Y

更新日期：2015-01-01 00:00:00

abstract：:The aim of this paper was to investigate whether sinoporphyrin sodium (DVDMS) could be a novel sonosensitizer in sonodynamic therapy. We used two kinds of leukemia cells (K562, U937) as main tumor cell models and cells (peripheral blood mononuclear cells, spleen lymphocytes) separated from healthy ICR mice as normal c...

journal_title：Anti-cancer drugs

authors： Hu J,Wang X,Zhang K,Wang P,Su X,Li Y,Huang Z,Liu Q

更新日期：2014-02-01 00:00:00

abstract：:Transcatheter arterial chemoembolization (TACE) is widely used to treat unresectable hepatocellular carcinoma (HCC). Recently, a fine-powder formulation of cisplatin (DDP-H) was developed in Japan. We aimed to compare clinical outcomes after TACE using epirubicin or DDP-H in patients with HCC. We evaluated 202 patient...

journal_title：Anti-cancer drugs

authors： Yodono H,Matsuo K,Shinohara A

更新日期：2011-03-01 00:00:00

abstract：:Verapamil, cyclosporin A (CsA), the cyclosporin derivative SDZ PSC 833 and the novel cyclopeptolide SDZ 280-446 were tested for their capacity to chemosensitize a P-glycoprotein (Pgp)-expressing multi-drug resistant (MDR) variant of the CEM human T lymphoblastoid cell subline (CCRF ACTD 400+). That MDR-CEM cell sublin...

journal_title：Anti-cancer drugs

authors： Jachez B,Loor F

更新日期：1993-12-01 00:00:00

abstract：:The results of several preclinical and clinical studies were reported by oncology professionals at the 43rd American Society of Clinical Oncology (ASCO) meeting, the largest international forum in which the latest achievements in cancer research are annually presented. The central theme this year was 'Translating Rese...

journal_title：Anti-cancer drugs

authors： Puglisi F,Aprile G,Fasola G

更新日期：2008-02-01 00:00:00

abstract：:In this study, we investigated the putative cytotoxic effect elicited by the garlic-derived compound S-allylcysteine (SAC) in two human cancer cell lines (HCC827 and NCI-H1975) in order to develop an experimental approach to the therapeutic potential of this molecule for lung cancer. Cells were incubated for 24, 48 an...

journal_title：Anti-cancer drugs

authors： Orozco-Morales M,Hernández-Pedro NY,Barrios-Bernal P,Arrieta O,Ruiz-Godoy LM,Aschner M,Santamaría A,Colín-González AL

更新日期：2021-02-01 00:00:00

abstract：:The objective of this study was to determine the safety and efficacy of intravesical novantrone in refractory superficial bladder cancer. The eligibility criteria included proven carcinoma in situ or superficial transitional cell carcinoma of the bladder at stage Ta or T1 that was proven refractory to or in relapse af...

journal_title：Anti-cancer drugs

authors： Sharifi R,Lee M,Clayton M,Lamb D,Siami P,Strub M,Albert D,Sarosdy M

更新日期：1991-04-01 00:00:00

abstract：:The plasma pharmacokinetics of a second generation anthracycline derivative, idarubicin (Ida), have been studied in 17 patients with acute myelocytic leukemia (AML) and high risk features. The drug (10 mg/m2) was given in a randomized cross-over design as 3 min and 2 h infusions for three consecutive days. Cytosine ar...

journal_title：Anti-cancer drugs

authors： Eksborg S,Björkholm M,Hast R,Fagerlund E

更新日期：1997-01-01 00:00:00

abstract：:In the APHINITY study (NCT01358877, BIG 4-11/BO25126/TOC4939G), pertuzumab added to trastuzumab and chemotherapy significantly improved invasive disease-free survival as adjuvant treatment for patients with HER2-positive early breast cancer. The objective of this analysis was to assess the pharmacokinetics of pertuzum...

journal_title：Anti-cancer drugs

authors： Luo Y,Li W,Jiang Z,Zhang Q,Wang L,Mao Y,Tjan-Heijnen VCG,Im SA,McConnell R,Bejarano S,Fumagalli D,Bines J,Wang B,Garg A,Kirschbrown WP,Xu B

更新日期：2019-09-01 00:00:00

abstract：:The type 1 insulin-like growth factor receptor (IGF1R) is overexpressed by many tumors, and mediates growth, motility and protection from apoptosis. Inhibition of IGF1R expression or function has been shown to block tumor growth and metastasis, and enhance sensitivity to cytotoxic drugs and irradiation. Thus the IGF1R...

journal_title：Anti-cancer drugs

authors： Bohula EA,Playford MP,Macaulay VM

更新日期：2003-10-01 00:00:00

abstract：:This study examined the growth inhibitory effects of combining 1,25-dihydroxyvitamin D3 (calcitriol) with retinoic acid or dexamethasone against cultured breast and ovarian carcinoma cells. Retinoic acid (12.5-50 nM) increased the effectiveness of calcitriol (12.5-50 nM) against MCF-7 and NIH:OVCAR3 cells, with synerg...

journal_title：Anti-cancer drugs

authors： Saunders DE,Christensen C,Williams JR,Wappler NL,Lawrence WD,Malone JM,Malviya VK,Deppe G

更新日期：1995-08-01 00:00:00

abstract：:Cerebral gliomas have a poor survival time even after multimodal treatment, because of the unavoidable recurrence of tumor. Several trials with a combination of old and new chemotherapics have been performed, but survival time remains generally less than 12 months. Tamoxifen (TAM) has recently been shown to inhibit th...

journal_title：Anti-cancer drugs

authors： Mastronardi L,Puzzilli F,Ruggeri A

更新日期：1998-08-01 00:00:00